Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PRA023
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Prometheus Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRA023, the company's lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A).
Brand Name : PRA023
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 03, 2021
Lead Product(s) : PRA023
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Prometheus Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NPT520-34
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Neuropore Therapies
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.
Brand Name : NPT520-34
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 13, 2020
Lead Product(s) : NPT520-34
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Neuropore Therapies
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?